Accuray Incorporated (NASDAQ:ARAY) Stake Raised by Perritt Capital Management Inc

Perritt Capital Management Inc lifted its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 139.3% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 120,000 shares of the medical equipment provider’s stock after acquiring an additional 69,864 shares during the period. Perritt Capital Management Inc’s holdings in Accuray were worth $218,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in ARAY. Assenagon Asset Management S.A. bought a new position in shares of Accuray in the second quarter worth $132,000. Williams & Novak LLC raised its holdings in Accuray by 259.2% during the second quarter. Williams & Novak LLC now owns 96,900 shares of the medical equipment provider’s stock worth $176,000 after purchasing an additional 69,925 shares in the last quarter. Heartland Advisors Inc. lifted its position in Accuray by 2.2% in the first quarter. Heartland Advisors Inc. now owns 2,919,200 shares of the medical equipment provider’s stock worth $7,210,000 after purchasing an additional 61,700 shares during the period. Jump Financial LLC bought a new position in Accuray during the 4th quarter valued at $140,000. Finally, First Eagle Investment Management LLC increased its position in shares of Accuray by 5.3% during the 4th quarter. First Eagle Investment Management LLC now owns 959,508 shares of the medical equipment provider’s stock valued at $2,715,000 after purchasing an additional 48,583 shares during the period. 64.08% of the stock is currently owned by institutional investors and hedge funds.

Accuray Trading Down 3.0 %

Shares of Accuray stock opened at $1.97 on Thursday. The business has a fifty day simple moving average of $1.91 and a 200-day simple moving average of $2.03. Accuray Incorporated has a fifty-two week low of $1.40 and a fifty-two week high of $3.10. The firm has a market cap of $195.51 million, a price-to-earnings ratio of -8.95 and a beta of 1.40. The company has a quick ratio of 0.78, a current ratio of 1.58 and a debt-to-equity ratio of 4.05.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported $0.03 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.03. The company had revenue of $134.29 million during the quarter, compared to the consensus estimate of $122.80 million. Accuray had a negative net margin of 3.48% and a negative return on equity of 33.39%. During the same period in the prior year, the company earned ($0.03) EPS. On average, equities analysts forecast that Accuray Incorporated will post -0.01 EPS for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.